ian carter

Mr. ian carter

orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RRRebecca J. Rockett
Rebecca J. Rockett
AAAlicia Arnott
Alicia Arnott
CLConnie Lam
Connie Lam
RSRosemarie Sadsad
Rosemarie Sadsad
VTVerlaine Timms
Verlaine Timms
VSVitali Sintchenko
Vitali Sintchenko

15 April 2003 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
WRWiliam Rawlinson
Wiliam Rawlinson
ZWZubair Waliuzzaman
Zubair Waliuzzaman
ICian carter
ian carter
YBYvonne C. Belessis
Yvonne C. Belessis
KGKatarnya M. Gilbert
Katarnya M. Gilbert
JMJohn R. Morton
John R. Morton
Children with asthma were studied during the Southern hemisphere winter and summer of 2001–2002. Human rhinovirus (hRV) was significantly associated

1 January 2020 in Virus Evolution
Verified
Journal Article
Open access
JEJohn-Sebastian Eden
John-Sebastian Eden
RRRebecca Rockett
Rebecca Rockett
ICian carter
ian carter
HRHossinur Rahman
Hossinur Rahman
JLJoep de Ligt
Joep de Ligt
AAAlicia Arnott
Alicia Arnott
The SARS-CoV-2 epidemic has rapidly spread outside China with major outbreaks occurring in Italy, South Korea, and Iran. Phylogenetic analyses of whole-genome sequencing data identified a distinct SARS-CoV-2 clade linked to travellers returning from Iran to Australia and New Zealand. This study highlights potential viral diversity driving the epidemic in Iran, and underscores the power of rapid genome sequencing and public data sharing to improve the detection and management of emerging infectious diseases.

1 December 2005 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
AGAllan R. Glanville
Allan R. Glanville
ASAndrew I.R. Scott
Andrew I.R. Scott
JMJudith M. Morton
Judith M. Morton
CAChristina L. Aboyoun
Christina L. Aboyoun
MPMarshall L. Plit
Marshall L. Plit
MMMonique A. Malouf
Monique A. Malouf

27 August 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
LHLinda Hueston
Linda Hueston
JKJen Kok
Jen Kok
AGAyla Guibone
Ayla Guibone
DMDamien McDonald
Damien McDonald
GHGeorge Hone
George Hone
MOMatthew Vincent Neil O'Sullivan
Matthew Vincent Neil O'Sullivan
Background: Testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibodies has become an important tool, complementing nucleic acid tests (NATs) for diagnosis and for determining the prevalence of coronavirus disease 2019 (COVID-19) in population serosurveys. The magnitude and persistence of antibody responses are critical for assessing the duration of immunity.Methods: A SARS-CoV-2-specific immunofluorescent antibody (IFA) assay for immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) was developed and prospectively evaluated by comparison to the reference standard of NAT on respiratory tract samples from individuals with suspected COVID-19. Neutralizing antibody responses were measured in a subset of samples using a standard microneutralization assay.Results: A total of 2753 individuals were eligible for the study (126 NAT-positive; prevalence, 4.6%). The median “window period” from illness onset to appearance of antibodies (range) was 10.2 (5.8–14.4) days. The sensitivity and specificity of either SARS-CoV-2 IgG, IgA, or IgM when collected ≥14 days after symptom onset were 91.3% (95% CI, 84.9%–95.6%) and 98.9% (95% CI, 98.4%–99.3%), respectively. The negative predictive value was 99.6% (95% CI, 99.3%–99.8%). The positive predictive value of detecting any antibody class was 79.9% (95% CI, 73.3%–85.1%); this increased to 96.8% (95% CI, 90.7%–99.0%) for the combination of IgG and IgA.Conclusions: Measurement of SARS-CoV-2-specific antibody by IFA is an accurate method to diagnose COVID-19. Serological testing should be incorporated into diagnostic algorithms for SARS-CoV-2 infection to identify additional cases where NAT was not performed and resolve cases where false-negative and false-positive NATs are suspected. The majority of individuals develop robust antibody responses following infection, but the duration of these responses and implications for immunity remain to be established.

18 March 2021 in Viruses
Verified
Journal Article
Open access
PDF file
RTRachel Tulloch
Rachel Tulloch
Jen KokJen Kok
Jen Kok
ICian carter
ian carter
DDDominic Dwyer
Dominic Dwyer
JEJohn-Sebastian Eden
John-Sebastian Eden
Human metapneumovirus (HMPV) is an important cause of upper and lower respiratory tract disease in individuals of all ages. It is estimated that most individuals will be infected by HMPV by the age of five years old. Despite this burden of disease, there remain caveats in our knowledge of global genetic diversity due to a lack of HMPV sequencing, particularly at the whole-genome scale. The purpose of this study was to create a simple and robust approach for HMPV whole-genome sequencing to be used for genomic epidemiological studies. To design our assay, all available HMPV full-length genome sequences were downloaded from the National Center for Biotechnology Information (NCBI) GenBank database and used to design four primer sets to amplify long, overlapping amplicons spanning the viral genome and, importantly, specific to all known HMPV subtypes. These amplicons were then pooled and sequenced on an Illumina iSeq 100 (Illumina, San Diego, CA, USA); however, the approach is suitable to other common sequencing platforms. We demonstrate the utility of this method using a representative subset of clinical samples and examine these sequences using a phylogenetic approach. Here we present an amplicon-based method for the whole-genome sequencing of HMPV from clinical extracts that can be used to better inform genomic studies of HMPV epidemiology and evolution.